Seasonal affective disorder (SAD) is a form of depression that people experience at a particular time of year or during a particular season. The change in the season highly affects the mood and energy levels, and lead to symptoms of depression that have a significant impact on day-to-day life.
Rising incidence of seasonal affective disorder (SAD) is expected to drive seasonal affective disorder market growth over the forecast period. For instance, according to an article published by the Hindawi Publishing Corporation-Depression Research and Treatment, in December 2015, reports that the people who lives farthest from the equator in northern latitudes are most susceptible towards SAD, for instance, in the U.S., 1.4% of those who live in Florida and 9.9% living in Alaska experience seasonal affective disorder.
However, side effects of seasonal affective disorder medication such as Bupropion is expected to hinder the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that the drug Bupropion, which is approved by the U.S. FDA exhibit several side effects such as tachycardia (cardiovascular disease), rhinitis and pharyngitis (respiratory diseases), and others.
- This report provides in-depth analysis of the global seasonal affective disorder market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global seasonal affective disorder market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., AbbVie, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global seasonal affective disorder market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global seasonal affective disorder market.
-
- Fall & Winter Seasonal Affective Disorder
- Spring & Summer Seasonal Affective Disorder
- Others
-
- Light Therapy, Medications
- Psychotherapy
- Counselling
- Others
-
- Hospitals
- Clinics
- Research Institutes
- Others
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Pfizer, Inc
- GlaxoSmithKline plc
- Johnson & Johnson Services Inc
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd
- Eli Lily and Company
- AbbVie Inc
- Hoffmann-La Roche AG
- Mylan, Inc
- Bausch Health
- Koninklijke Philips N.V.
- Bayer AG
- Allergan
- Bristol-Myers Squibb
- Henry Schein Inc
